theranostics
Telix Pharmaceuticals, Cardinal Health Partner to Distribute Prostate Cancer Imaging Agent in US
Cardinal is using its own cyclotron installations to produce Gozellix for distribution across a range of US locations.
Telix Pharmaceuticals Begins Phase I Trial of Radiopharmaceutical Agent in Sarcoma
The firm is evaluating its radiopharmaceutical imaging agent targeting PDGFRα, TLX300-CDx, in advanced or metastatic soft tissue sarcoma.
The firm presented early data for a blood-based approach to screen prostate cancer patients for PSMA, which it believes has advantages over PET imaging.
Telix Pharmaceuticals to License FAP-Targeting Radiopharmaceuticals From German Researchers
The firm is paying €7 million to add fibroblast activation protein-targeting assets to its pipeline, which it will initially develop for bladder cancer.
Alpha-9 Oncology Raises $175M in Series C Financing
The firm will use the funds to advance its pipeline of radiopharmaceutical agents, including an imaging agent currently being studied in melanoma.